No title
Background. Treatment of childhood medulloblastoma has evolved to reduce neurotoxicity while improving survival. However, the impact of evolving therapies on late neurocognitive outcomes and adult functional independence remains unknown. Methods. Adult survivors of childhood medulloblastoma (n = 505; median [minimum–maximum] age, 29 [18–46] years) and sibling controls (n = 727; 32 [18–58] years) f
